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Up-regulated MHC-class II expression and y-IFN and soluble IL-2R in
lupus nephritis. Expression of MHC-class II molecules (HLA-DR and
-DQ), serum gamma-interferon (y-IFN) and soluble interleukin-2 recep-
tor (sIL-2R) levels were studied in 35 Japanese patients with lupus
nephritis (LN) to clarify intraglomerular cellular activation and cytok-
me involvement in human LN. In 11 normal kidney specimens, HLA-
DR(Ial) was noted in glomerular tufts, but HLA-DQ was either not or
was faintly detected in glomeruli by the indirect immunofluorescence
technique. HLA-DR and -DQ were observed mainly on the surface of
glomerular endothelial cells in 100% and 50% of 28 lupus kidney
specimens except for necrotic or sclerotic lesions. HLA-DQ was
expressed in a high incidence of 67%, 86% in patients with proliferative
LN (WHO Class 1II-IV) and active lesions, respectively. Serum y.IFN
and sIL-2R levels were 1.2 0.2U/mI and 190 24 U/mI (mean SEM;
N = 30) in normal controls, and elevated in patients with proliferative
LN (4.1 1.0 U/mI, 383 81 U/mI, N = 25), especially with active
lesions (6.2 1.5 U/mI, 500 110 U/mI, N = 14). Overall, glomerular
lesions such as HLA-DQ expression, the activity index and leukocyte
infiltration correlated positively with serum y-IFN levels (r = 0.55; P <
0.01 for HLA-DQ, r = 0.68; P < 0.001 for activity index, r = 0.38; P <
0.05 for leukocyte infiltration), but not with serum sIL-2R levels,
anti-DNA antibody titers and CH5O titers. The aberrant expression of
HLA-DQ in glomeruli was significantly reduced by treatment with
methylprednisolone pulse therapy, concomitant with normalization of
serum y-IFN and sIL-2R levels. We conclude that the aberrant expres-
sion of MHC-class II molecules in glomeruli and serum y-IFN concen-
trations are related to the proliferative and active lesions including
leukocyte infiltration of human LN, and these abnormalities in vivo are
improved by methylprednisolone pulse therapy. These results suggest
that MHC-class II molecules and y-IFN may play an important role in
the tissue injury of human LN.
Major histocompatibility complex (MHC)-class II molecules
(HLA-DRIDQ/DP antigens) take part in immunoresponse
mechanism of CD4 positive T cells, and are generally present
on immunoregulatory cells such as macrophages and B cells [11.
It has also been recognized that the aberrant MHC-class II
molecules are expressed on the target cells of immune diseases
[2]. In the kidney of systemic lupus erythematosus (SLE),
expression of MHC-class II molecules on glomerular endothe-
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hal cells and tubular epithelial cells have been reported for both
human and animal models [3, 4]. These induction of MHC-class
II molecules suggest cytokines' activation in vivo, because
gamma-interferon (y-IFN) can enhance or induce MHC-class II
molecules on endothelial cells and other cell types [5—8]. As for
the involvement of MHC-class II molecules and y-IFN in renal
injury, we reported previously that elevated serum y-IFN levels
correlated with the enhanced glomerular expression of MHC-
class II molecules and endocapillary proliferation with leuko-
cyte infiltration upon an acute exacerbation of IgA nephropathy
[9]. Madrenas, Parfrey and Halloran [10] showed the induction
of MHC-class II molecules mediated by y-IFN and the reduc-
tion of these induced expression by treatment of monoclonal
antibody against y-IFN in a HgCI2-induced autoimmune disor-
der with glomerulonephritis in rodents. Recently, Kelly et al
found that y-IFN and tumor necrosis factor (TNF)-a can induce
or enhance the aberrant MHC-class II molecules and intercel-
lular adhesion molecule-i (ICAM-l) on renal tubular epithelial
and mesangial cells of autoimmune animal model mice (MPL/
MPJ-lpr/lpr; MPL/lpr and the Fl hybrids of the New Zealand
Black and White; NZB/W Fl) in vivo and in vitro [11, 12].
SLE is also characterized by impaired T cell function and
polyclonal B cell activation [13]. Activation and proliferation of
T and B cells as well as monocyte is associated with expression
and sequent release of interleukin 2 receptors (IL-2R) into the
milieu as a result of proteolysis occurring on the cell surface or
after membrane internalization [14, 15]. High serum soluble
IL-2R (sIL-2R) concentration has been reported in NZB/W Fl
mice [161, human SLE [17—20] and other autoimmune diseases
[19], however, the biologic roles of sIL-2R and its effects in
human LN remain to be determined.
In the NZB/W Fl mice, it has been reported that recombinant
murine -IFN treated mice accelerate development of fatal
immune complex glomerulonephritis [211, and that administra-
tion of monoclonal antibody specific for y-IFN [21] or IL-2R
[22] to such mice resulted in significant remission. These
experiments suggest that y-IFN and IL-2R might have a major
biological role in immune regulation causing the development of
murine LN. In human SLE, Machold and Smolen reported a
patient with presumed rheumatoid arthritis (RA) who devel-
oped a life threatening multiorgan flare of SLE including
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proteinuria after administration of recombinant y-IFN for treat-
ment RA [231. However, little information has been presented
concerning the relation between the intraglomerular immuno-
logical activity of human LN and serum y-IFN or sIL-2R levels.
The aim of this study was to analyze the roles of the aberrant
expression of MHC-class II molecules (HLA-DR/DQ antigens)
in glomeruli, serum y-IFN and sIL-2R levels, and the therapeu-
tic effect of methyiprednisolone pulse therapy for these param-
eters in human LN. The studies show that serum y-IFN levels
relate to the intraglomerular HLA-DQ expression, proliferative
and active lesions including leukocyte infiltration of human LN,
and that methyiprednisolone pulse therapy improves both sero-
logical and pathological activity of human LN.
Methods
Patients
From April 1987 to March 1991, 35 Japanese patients (4 males
and 31 females) with SLE diagnosed by the adequate evalua-
tions of the 1982 American Rheumatism Association [24] were
studied at the Kanazawa University Hospital. The duration
from the apparent onset of disease ranged from one month to 14
years with mean 3.9 years. Twenty-nine patients were pre-
treated with oral prednisolone alone, and six with no therapy.
During study period, patients had been assigned to one of three
groups according to their clinical state: (I) oral prednisolone
alone (daily dose with 10 to 20 mg), patients with proteinuria
less than 1.0 g/day; (2) a combination of prednisolone (daily oral
dose with 10 to 20 mg) and a new immunosuppressive drug,
mizoribine (daily oral dose with 3 mg/kg of body weight) [25];
patients with diffuse proliferative LN without active lesions
(DPLN, WHO Class IVd) or membranous LN (MLN, WHO
class V) showing moderate proteinuria (1.0 to 3.5 g/day); (3)
methyiprednisolone pulse therapy (intravenous injection of
1000 mg/day for 3 days every 2 or 3 weeks) and oral pred-
nisolone (daily dose with 20 to 40 mg), patients with clinically
and/or pathologically active LN with moderate to massive
(more than 3.5 g/day) proteinuna and/or gross hematuria. This
study was approved by the drug ethics committee of Kanazawa
University Hospital. All patients included in the present anal-
ysis underwent one or two renal biopsies. The first renal biopsy
was performed on the patient's entry into this study. Second
biopsies were obtained from nine patients after they had treated
by pulse therapy or combination therapy for four to eight
weeks. Patients were excluded if medical or personal consider-
ations that rendered a repeat biopsy unacceptable. Eleven
kidney specimens showing minor glomerular abnormality ob-
tained from normal portion of three resected kidneys or by
biopsy from eight patients with non-glomerular gross hema-
tuna; four males and seven females aged ranging from 17 to 67
years with a mean of 37 years, were examined as the controls.
Methods
Light microscopic studies. Forty-four kidney specimens were
fixed with 10% phosphate-buffered formalin (pH 7.4), embed-
ded in paraffin, cut into 4 m sections, and stained with
hematoxylin and eosin, periodic acid Scuff's reagent, periodic
acid silver methenamine and Mallory-azan solutions.
The specimens were examined mainly focusing on mesangial
cell proliferation, extracapillary lesions (cellular and fibrous
crescents), endocapillary proliferation including leukocyte infil-
tration counted by light microscopy and judged as positive by
more than three polymorphonuclear cells and/or mononuclear
cells in each glomerulus, karyorrhexis and fibrinoid necrosis,
hyaline deposits, glomerular sclerosis, interstitial inflammation
and fibrosis, and tubular atrophy. Each parameter was graded
on scale of 0 (absent), 1 (mild), 2 (moderate) and 3 (severe) as
described by Austin et a! [261. World Health Organization
(WHO) criteria were used for the light microscopic classifica-
tion of the major forms and the active lesions of LN [27]. The
"activity index (Al)" and "chronicity index (CI)" of the
histological appearance were also calculated according to the
methods of National Institute of Health (NIH) by Austin et al
126]. Two active lesions, fibninoid necrosis and cellular cres-
cents, were each arbitrarily weighted by a factor two on the
assumption, because these features were disproportionately
more ominous than the other active lesions.
Immunohistochemical studies. Twenty-eight fresh tissue spec-
imens, embedded in O.C,T. compound and snap-frozen in
n-hexane cooled with a mixture of dry ice and acetone, were cut
at 6 sm on a cryostat (Tissue-Tek II systems; Miles, Naperville,
Illinois, USA). MHC-class II molecules were detected by the
indirect immunofluorescence (IF) technique using murine
monoclonal antibodies; anti-human HLA-DR (Cappel, West
Chester, Pennsylvania, USA; No. 0101-2007), anti-lal (Ortho-
mune OKIa1, Ortho, Raritan, New Jersey, USA), anti-human
HLA-DQ (Leu 10, Becton-Dickinson, Mountain View, Califor-
nia, USA; No 7540) and anti-human class II (DQ) (clone No.
BU46; Bindingsite, Birmingham, UK). These murine monoclo-
nal antibodies were counter-stained with fluorescein isothiocy-
anate (FITC)-labeled anti-mouse IgG sheep IgG/(Fab')2 anti-
body, which has been proven to have no cross-reactivity to
human IgG (Cappel, No. 1311-1744). The double-staining IF
technique using rhodamin-conjugated anti-human IgG (y-chain)
goat IgG antibody (Cappel, No. 2201-0081) was performed in
some specimens. These specimens were observed under a
fluorescence microscope (Zeiss, Oberkochen, Germany). Posi-
tive controls run for each antibody (lymph node section) and
internal negative controls were processed. More than three
glomeruli were examined in each specimen, and intraglomerular
staining for HLA-DR and -DQ was arbitrarily graded on a scale
0 to 3 (negative, scattered, weakly diffuse, strongly diffuse) and
was calculated as the mean score of intraglomerular staining.
Specimens given as the mean score of more than 1.0 were
considered to be HLA-DR or -DQ-positive.
Immunoelectron microscopic studies. For indirect immuno-
peroxidase-electron microscope (pre-embedding method),
specimens were fixed with 2 to 4% periodate-lysine-paraform-
aldehyde solution at 4°C for four hours, dehydrated with
sucrose solution (10%, 15%, 20% each for 4 hr), embedded in
O.C.T. compound and snap-frozen in n-hexane cooled with a
mixture of dry ice and acetone and cut into thin sections. This
was followed by sequential over night incubation at 4°C with the
anti-HLA-DR or -DQ antigen murine monoclonal antibodies at
the appropriate dilutions, and were counter-stained with perox-
idase-conjugated anti-mouse IgG sheep IgG/(Fab')2 antibody
(Cappel, No. 3311-1744). Finally the sections were treated with
diaminobenzidine (DAB) [0.33 mglml in 100 m Tris-HC1 (pH
8.0) buffer with 0.005% 11202], fixed with 1% osmium tetroxide,
dehydrated with an alcohol series, embedded in Epok 812 resin,
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cut at 0.1 sm on an Ultra-microtome (LKB-III, Bromma,
Sweden) and observed under an electron microscopy (Hitachi
H-600, Tokyo, Japan).
y-IFN and sIL-2R assay. Sera, obtained at the renal biopsy
and stored at —70°C, were analyzed by solid-phase enzyme-
linked immunosorbent assay based on the double sandwich
principle using two murine monoclonal antibodies directed
against non-overlapping epitopes on human y-IFN (MD-i,
MD-2 [281) (HBT human gamma-interferon kit, DO3S, Holland
biotechnology, Leiden, the Netherlands) and human IL-2R
a-chain (p55; Tac antigen) (free IL-2 receptor kit, Eurogenetics,
Tessendelo, Belgium). Color intensity was measured by a
micropiate photometer (MTP-22, Corona Electric Co, Tokyo,
Japan) with measuring levels ranging from 0 to 50 U/mi for
y-IFN and 0 to 1000 U/ml for sIL-2R, respectively. Sera from 30
Japanese age- and sex-matched healthy volunteers, 4 males and
26 females aged from 16 to 67 with a mean of 35 years, were
examined for control purposes. All sera were obtained from
patients and volunteers when any other immunological active
states such as infections were excluded by clinical findings and
a questionnaire.
Anti-DNA antibody titer and total complement activity.
Anti-DNA antibody titers were measured with radioimmunoas-
say (anti-DNA kit II, Amersham, Tokyo, Japan), and total
complement activity (CH5O; new one point CH5O kit, Kyowa,
Tokyo, Japan) was assessed by the Mayer's 50% hemolysis
method.
Statistics
Statistical analyses were performed using paired and un-
paired Student's t-test, Wilcoxon single-rank sum test, Fisher's
exact test, and Pearson's and Spearman's correlation coeffi-
cient for the analysis of parametric and nonparametric data. P
<0.05 was accepted as statistically significant.
Results
Patients
Age of the patients ranged from 14 to 63 years at biopsy (37
2 years; mean SEM). Proteinuria of variable amounts and/or
microscopic hematuria were present in all the patients. Ne-
phrotic syndrome at the biopsy was observed in eight patients
(23%) and hypertension in ten (29%). Six patients (17%) pre-
sented with impairment of renal function (serum creatinine
levels >1.5 mg/dl). Serum anti-DNA antibody titer was ele-
vated in all of 35 patients with values 7 to 3980 U/mi (normal
range, <7 U/mi). Twenty-eight patients showed decreased
serum CH 50 titers below 32 U/mi (normal range, 32 to 47
U/mi). During study period, 17 patients were treated with oral
prednisolone alone (daily dose with 10 to 20 mg), 5 patient' with
a combination of prednisolone and mizoribine, and 13 patients
with methyiprednisoione pulse therapy and oral prednisolone.
Histopathological findings and HLA-DR(Ial) and -DQ
expression in glomeruli
In 11 normal kidney specimens, HLA-DR and lal were noted
in endothelial and some parts of mesangial region in glomeruli,
and peritubular capillary endothelial cells. The means scores of
HLA-DR(Ial) were more than 2.0 in all specimens. HLA-DQ
was detected in only a few glomerular and peritubuiar capillar-
ies (Fig. la). The mean scores of HLA-DQ were below 1.0 in all
specimens and judged as negative (Table 1).
Glomerular appearances were classified on optical micros-
copy as minor abnormality (WHO Class I) in 10 patients, focal
proliferative LN (PLN, WHO Class III) in 13, DPLN in 12,
rapidly progressive LN (RPLN, WHO Class IV with fresh
cellular crescent more than 80% of glomeruli) in three, and
membranous LN (MLN, WHO Class V) in six (Table 2). The
activity index ranged from 0 to 19 (mean 2.8 0.8, N = 35) and
the chronicity index from 0 to 10 (mean 1.4 0.4). Some degree
of glomerulosclerosis were found in 12 patients (34%), eight
patients with sclerotic lesions less than 25% of glomeruli, three
patients from 25 to 50%, and another patient with more than
50% of sclerotic glomeruli calculating the chronicity index as
10.
HLA-DR(Ial) was positive in glomerular endothelial cells
and some parts of mesangial region in all 28 specimens with
lupus nephritis examined (Fig. lb), however, HLA-DR expres-
sion was reduced or disappeared in necrotic or sclerotic lesions
in glomeruli. An immunoelectron microphotograph revealed
intense staining for HLA-DQ antigen on the surface of endo-
thelial cells in glomerular capillary lumen, but not epithelial
cells nor distinct mesangial cells in LN (Fig. ic). The aberrant
expression of HLA-DQ in the glomerular tufts with the mean
score more than 1.0 was observed in 50% of 28 specimens
tested, and was presented in a high incidence of 67% and 86%
in patients with proliferative LN (WHO Class III-IV, N = 19)
and active lesions (N 14), respectively (Tables 1 and 2).
The score of the activity index was significantly higher in
specimens with glomerular HLA-DQ-positive staining, being
measured at 6.6 1.6 (N = 14), compared with HLA-DQ-
negative at 1.3 0.5 (N = 14; P < 0.01). There was no
significant difference in the chronicity index between HLA-DQ-
positive and -negative patients (2.2 0.8 vs. 1.7 0.7).
Analysis of serum y-IFN and sIL-2R levels
In normal controls, serum y-IFN levels ranged 0 to 2.8 U/mI
(mean 2 SD, N = 30). Serum y-IFN level was significantly
higher in patients with SLE (3.6 0.8 U/mi, N = 45, P < 0.01),
especially with active lesions of LN (6.2 1.5 U/ml, N = 14, P
<0.005, Table 1). The mean serum y-IFN levels were high in
patients with PLN, DPLN and RPLN (4.3 1.9 U/ml, 4.0 0.8
U/mi, 9.0 0.8 U/mI, respectively, Table 2).
Serum sIL-2R level was 233 44 U/mI for the entire group of
SLE patients (N = 40) and 190 24 U/ml for the control group(N = 30). The difference was not significant. However, the
mean serum sIL-2R levels were significantly high in patients
with the active lesions of LN, DPLN and RPLN, being mea-
sured at 500 110 U/ml, 388 110 U/mI and 768 320 U/mI,
compared to normal control and patients without active lesions
(P < 0.05, respectively, Tables 1 and 2). There were no
significant changes of serum y-IFN and sIL-2R levels in minor
abnormality (WHO Class I) and MLN (WHO Class V).
Expression of HLA-DQ and endocapillary proliferation in
glomeruli and serum y-IFN levels
The mean serum y-IFN level was significantly higher in
HLA-DQ-positive patients, being measured at 6.9 1.7 U/mi,
compared with the HLA-DQ-negative patients at 1.3 0.3
I 
Fig. 1. Immunohistochemical Studies.
A. HLA-DQ expression in normal kidney
specimen was detected by the indirect
immunofluorescence technique using murine
monoclonal antibody anti-human HLA-DQ
(clone BU46). HLA-DQ antigen was positive
in some peritubular capillary walls (arrows),
but not in glomerular tufts (x 300). B. HLA-
DQ expression and IgG deposition in DPLN
were detected by the double-staining
immunofluorescence technique using
rhodamin-conjugated anti-human IgG (red)
and anti-HLA-DQ (LeulO, green). HLA-DQ
antigen was found along the glomerular and
peritubular capillary walls and in certain
mesangial areas. IgG appeared as
mesangiocapillary deposits (x 300). C.
Immunoelectron microphotograph using
immunoperoxidase method revealed intense
staining for HLA-DQ antigen (arrowheads) on
the surface of endothelial cells (Ed) in
glomerular capillary lumen, but not epithelial
cells (Ep) nor distinct mesangial cells (Mes) in
LN (original magnification x 3000).
Publication of this figure in color was made
possible by a grant from Asahi Chemical Co.,
LTD, Tokyo, Japan.
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U/mi (P < 0.05, Fig. 2). In addition, expression of HLA-DQ in
glomeruli was found in 11 of the 12 patients with serum y-IFN
levels which were above the upper limit of the normal range
(that is, above 2.8 U/mi; Fig. 2). In 14 patients with endocapil-
lary proliferation including leukocyte infiltration, the incidence
of glomerular HLA-DQ expression and serum y-IFN levels
were significantly higher than those of 12 patients without
endocapillary proliferation (86 vs. 17%; P < 0.05 for HLA-DQ
and 6.6 1.7 U/mI vs. 1.8 0.4 U/mi; P < 0.05 for serum
y-IFN level; Fig. 3).
Correlations
Overall, there was significant association between serum
y-IFN and sIL-2R levels (r = 0.67, P < 0.01, N 36; Fig. 4).
However, there was no significant relation between serum
y-IFN or sIL-2R levels and serum anti-DNA antibody or CH5O
titers. As the pathological correlations, the activity index cor-
related with glomerular HLA-DQ expression (r = 0.54, P <
0.01) and serum y-IFN level (r 0.68, P < 0.01; Table 3). As
expected, leukocyte infiltration was highly associated with
intraglomerular HLA-DQ expression (r = 0.61, P < 0.001).
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Glomerular
expression
Serum concentration
Gamma-IFN
U/mi
sIL-2R
lU/miHLA-DR HLA-DQ
Control 100% 0% 1.2 0.2 190 24
N II 11 30 30
SLE 100% 50% 3.6 0.8 233 44
N 28 28 45 40
LN with 100% 86% 6.2 1.5 500 1l0
active lesions
N 14 14 14 14
LN without 100% 14% 2.1 0.4a 155 16
active lesions
N 14 14 29 26
Values are means SEM. Abbreviations are: LN, lupus nephritis;
IFN, interferon; sIL-2R, soluble interleukin-2 receptor.
a P < 0.05 or less vs. control by Student's t-test
.
Histological findings
Glomerular
expression
Serum concentration
Gamma-IFN sIL-2R
(WHO classes) HLA-DR HLA-DQ U/mi lU/mi
Minor abnormality 100% 0% 1.1 0.2 175 20
(Class I, N = 10) (N = 6) (N = 6) (N = 10) (N = 9)
Focal proliferative LN 100% 43% 4.3 l.9a 193 37
(ClassIII,N=13) (N=7) (N=7) (N=13) (N1l)
Diffuse proliferative LN 100% 80% 4.0 0.8 388 I l0
(ClasslV,N= 12) (N= lO)(N= 10) (N= 12) (N= 12)
Rapidly progressive LN 100% 100% 9.0 0.8a 768 320
(Class IVa/b, N = 3) (N = 2) (N = 2) (N = 3) (N = 3)
Membranous LN 100% 33% 2.5 0.9 157 27
(Class V, N = 6) (N = 3) (N = 3) (N = 6) (N 6)
Values are means SEM. Abbreviations are: LN, lupus nephritis;
IFN, interferon; slL-2R, soluble interleukin-2 receptor.
a P < 0.05 or less vs. control and class I by Student's t-test
However, serum sIL-2R, anti-DNA antibody and CH5O titers
did not relate to HLA-DQ expression, the activity index and
leukocyte infiltration. In contrast, the chronicity index did not
correlate with HLA-DQ expression, serum y-IFN levels, serum
sIL-2R levels, serum anti-DNA antibody and CH5O titers.
Effect of methyiprednisolone pulse therapy
The clinical effects of pulse therapy judged by serum anti-
DNA antibody and CH5O titers were significantly improved at
four to eight weeks after the initial pulse therapy (473 298
lU/mi vs. 31 25 lU/mi; P < 0.025 for anti-DNA antibody
titers, 21 2 U/mI vs. 30 3 U/mI; P < 0.01 for CH5O titers,
N = 13). In morphology, the activity index was significantly
improved from 6.2 1.8 to 1.4 0.4 (N = 8, P < 0.025) after
therapy, however, there were no significant changes in the
chronicity index (1.3 0.3 vs. 1.4 0.3, N = 8).
Serum y-IFN and sIL-2R levels were significantly decreased
after pulse therapy (5.9 1.9 U/mI vs. 2.0 0.7 U/mi; P <0.05
Control DO negative DO positive
(N=30) (N=14) (N=14)
Fig. 2. Relationship between glomeruiar HLA-DQ expression and
serum gamma-interferon levels in patients with lupus nephritis. The
shaded area indicates the normal range (mean 2 sD; 0 to 2.8 U/mI).
for y-IFN, 444.9 105.6 U/ml vs. 189.9 37.6 U/ml; P < 0.05
for sIL-2R). Kidney samples before pulse therapy were avail-
able from 12 patients; there was strong reactivity to HLA-DQ in
glomerular tufts of eight samples, and in seven there was a
disappearance of HLA-DQ after treatment. High y-IFN and
sIL-2R levels persisted after pulse therapy in one patient who
showed a consistent expression of HLA-DQ in glomeruli, but
the y-IFN level fell to within normal range in six other patients
who showed no HLA-DQ staining in glomeruli after treatment
(Fig. 5a, b).
Discussion
The results of the present study indicate that glomerular
aberrant expression of HLA-DQ antigen and serum y-IFN
levels are related to the activity index and endocapiliary prolif-
eration including leukocyte infiltration of human LN, and that
serum sIL-2R levels correlate with serum y-IFN levels, but not
with the activity of human LN.
Expression of MHC-class II molecules in glomeruli, HLA-
DR(Ial) antigen was localized to the endothelial cells of gb-
merular and peritubular capillaries and some part of the mesan-
gial region in normal kidney specimen and lupus nephritis
except for necrotic or sclerotic lesions in glomeruli, as de-
scribed previously by Hinglais et a! [29]. In MRL/lpr mice,
Wuthrich et al [4] reported enhanced MHC-class II (Ia) antigen
expression in the glomerular capillary and mesangium. Our
findings of HLA-DR and lal antigen expression in glomeruli are
similar to these animal models. Expression of HLA-DQ antigen
Table 1. Glomerular expression of MHC-class II antigens, and serum
gamma-IFN and soluble IL-2R levels in lupus nephritis
(0
>
0)
C0
1)
C
E
E
0)
E
(I)
Table 2. Glomerular expression of MHC-class II antigens and serum
gamma-IFN and soluble IL-2R levels in WHO classes of lupus
nephritis
0S
25.2
• 10.7
S
•55
ci)
C0
ci,
C
E
E
cci0)
E
ci)
Cl)
Endocapiuary proliferation and/or
leukocyte infiltration
Fig. 3. Relationship between endocapillary proliferation including leu-
kocyte infiltration and serum gamma-interferon levels in patients with
lupus nephriiis. The groups differ significantly (P < 0.05). Symbols are:(S) HLA-DQ positive in glomeruli; (0): HLA-DQ negative in
glomeruli.
is usually selected for a marker of endothelial cell activation in
vivo, because the basal expression is markedly less than other
class II molecules [61. In this study, HLA-DQ was observed by
the indirect immunofluorescence technique using two murine
monoclonal antibodies (Leu 10 and BU46), and was detected in
peritubular capillaries of both normal and lupus kidney speci-
mens, and glomerular tufts in human PLN or DPLN, correlated
with the activity index and endocapillary proliferation including
leukocyte infiltration except for necrotic or sclerotic lesions
in glomeruli, but not or faintly in glomerular tufts of normal
kidney specimens. Immunoelectron microphotographs revealed
HLA-DQ antigen on the surface of endothelial cells in glomer-
ular tuft, but not epithelial cells nor distinct mesangial cells.
HLA-DR and -DQ positive cells detected in mesangial regions
might be immuno-active infiltrating cells such as macrophases
or activated T cells. Muller et al [30] analyzed 15 normal kidney
biopsies using the indirect immunoperoxidase method, and
found that HLA-DQ antigen was only observed on distinct
glomerular cells which appeared to be present within the
mesangial region and rarely in capillaries. They also reported
that a decrease of intraglomerular HLA-class II positive cells
was seen in kidney biopsies of 10 patients with rapidly progres-
sive glomerulonephritis, including four patients with SLE, and
were especially sclerotic lesions, but crescents in RPGN fre-
U)
ci,
0
0.
ci)0
ci)
ci)
0
U)
Glomerular
findings
HLA-DQ
expression
Activity
index
Chronicity
index
Leilkocyte
infiltration
HLA-DQ —
—
r = 0.54
P < 0.01
r =
—0.03
NS
r = 0.61
P < 0.001
Gamma-IFN r = 0.55
P < 0.01
r = 0.68
P < 0.001
r =
—0.06
NS
r = 0.38
P < 0.05
sIL-2R r = 0.13
NS
r = 0.21
NS
r = 0.08
NS
r = 0.14
NS
Anti-DNA titer r = 0.07
NS
r = 0.28
NS
r =
—0.11
NS
r = 0.28
NS
CH5O r = 0.13
NS
r
—0.22
NS
r = 0.16
NS
r =
—0.31
NS
quently contained a large number of HLA-DQ positive cells
[301. These differences of HLA-DQ expression in glomeruli
might be the result using the different methods, because we also
examined some normal and diseased kidney specimens by the
avidin-biotinylated-alkaline-phosphatase method which is more
sensitive than the indirect immunoperoxidase method, and
detected the intraglomerular HLA-DQ expression even in nor-
mal kidney specimens, but failed to show the quantitative
difference in each specimen except for staining loss in sclerotic
or necrotic lesions (unpublished data). We chose the indirect IF
technique in this study, because this method was more suitable
to detect the dynamic changes of HLA-DQ expression in
glomeruli. Our findings indicate that expression of HLA-DQ
antigen is a lower level than other MI-IC-class II molecules
(HLA-DR) and less frequent in normal glomerular endothelial
cells, and that the glomerular endothelial cells are activated in
human LN, and that MHC-class II molecules disappear in
necrotic or sclerotic glomerular tufts as the result of endothelial
cell injury or loss. These up-regulated changes of MHC-class II
antigens might be correlated with leukocyte adhesion (exuda-
tive change) and interaction with T cells, especially CD4
U
U
U
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Fig. 4. Correlation between serum gamma-interferon and soluble in-
rerleukin 2 receptor levels in lupus nephritis (r = 0.45, P < 0.01; N =
38).
Table 3. Correlation of glomerular HLA-DQ expression, serum
gamma-IFN, soluble IL-2R levels, compliments and serum anti-DNA
antibody titer in lupus nephritis
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Methylprednisolone pulse therapy
Fig. 5. Methylprednisolone pulse therapy. (A) Alteration of serum
gamma-interferon levels and glomerular HLA-DQ expression following
methyiprednisolone pulse therapy in patients with lupus nephritis.
Symbols are: (•) HLA-DQ positive in glomeruli; (0) HLA-DQ nega-
tive in glomeruli; (0) examination not performed; the shaded area
indicates the normal range (mean 2 so; 0 to 2.8 U/mI). (B) Alteration
of serum soluble interleukin-2 receptor levels following methyiprednis-
olone pulse therapy in patients with lupus nephntis, the shaded area
indicates the normal range (mean 2 SD; 0 to 485 lU/mi).
positive cells (antigen presentation) at acute inflammatory
changes in human LN.
It is well known that y-IFN augments the expression of
MHC-class I antigens and induces class H molecules. This
Following therapy
induction of MHC-class II antigen expression on endothelial
cells in vitro appears first about 12 to 24 hours after exposure of
y-IFN, reaches plateau by four to six days and persists for at
least four days despite removal of y-IFN from culture superna-
tant [71. In vivo, elevated endogenous y-IFN, such as graft-vs.-
host disease [31], and continuous intravenous infusion of
recombinant y-IFN [32] induced MHC-class II molecules in
almost every cell type. As for an involvement of y-IFN in
murine LN, Jacob, van der Meide and McDevitt [21] reported
an excellent work in which the treatment of recombinant y-IFN
resulted in an increased incidence of LN and death in NZB/W
Fl mice, while blocking the effect of y-IFN by monoclonal
antibody down-regulated such a process. The relation between
y-IFN and human SLE has been reported by some workers [33,
34], however, their exact role in the pathogenesis of human LN
is still unclear. In this work, we showed that serum y-IFN levels
were high in patients with PLN, DPLN and RPLN, and
correlated with the up-regulated expression of MHC-class II
molecules in glomeruli and the pathological activity of human
LN such as activity index, endocapillary proliferation and
leukocyte infiltration. In addition, Machold and Smolen re-
ported a patient who developed a life-threatening multiorgan
flare of SLE including proteinuria after administration of
recombinant y-IFN [23]. These findings strongly suggest that
y-IFN induces and accelerates human LN in addition to the
up-regulated expression of MHC-class II gene products, which
is similar to the observation in lupus mice models. We also
observed the same phenomena such as the up-regulated expres-
sion of MHC-class II antigens and elevated serum y-IFN in IgA
nephropathy, especially in acute exacerbation [9]. These results
suggest that the up-regulated cytokines and MHC-class II
molecules may accelerate the acute inflammatory process in
glomerular injury of nephritis, but may not be specific for LN.
With respect to the chronicity index, the lack of differences in
glomerular HLA-DQ expression and serum y-IFN levels sug-
gests that chronic lesions of human LN are probably caused by
other mechanisms, as previously described by Alexopoulos et
al [35], and that interstitial monocytes may be the major factor
of chronic injury of human LN. However, further investigation
is necessary for establishing the exact roles of cytokines in renal
injury of human LN.
In both human and animal SLE, elevated serum sIL-2R levels
were reported to associate with hypocomplementemia and
disease activity [16—20]. In addition, Kelly et a! [22] reported
that administration of specific monoclonal antibody for IL-2R
resulted in significant remission of LN in NZBIW Fl mice. We
found that serum sIL-2R levels correlated positively with serum
y-IFN levels and were high in patients with the active lesions of
LN, DPLN and RPLN. However, there were no significant
correlations between serum sIL-2R levels and the up-regulated
expression of MHC-class II molecules in glomeruli nor the
pathological activity of human LN. These findings indicated
that serum sIL-2R levels reflected in vivo T lymphocyte acti-
vation resulting in cytokines' production such as y-IFN, but did
not directly affect glomerular injury of human LN. These
results suggest that anti-IL-2R antibody may indirectly resolve
the glomerular injury by suppression of activated T lympho-
cytes or other IL-2R bearing cells.
As for treatment of human LN, corticosteroids and immuno-
suppressants (cytotoic drugs) were used and improved the
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prognosis of both human and animal LN [36]. Clinical improve-
ment of LN by high doses of intravenous methyiprednisolone
was noted that patients with active renal disease; especially
clinical oliguric renal failure or pathological diffuse proliferative
LN had the most impressive results [37, 38]. However, the
exact mechanism of these effects in glomeruli is still unclear.
Groenewegen, Burman and van der Linden [39] reported that
MHC-class II molecule positive glomerular and peritubular
endothelial cells do not express these antigens during treatment
with immunosuppressants such as cyclosporin A. In this study,
serum y-IFN and sIL-2R levels and the aberrant expression of
HLA-DQ antigen in glomeruli were markedly improved in all
patients except one treated with pulse therapy. We hypothesize
that pulse therapy may induce clinical and pathological resolu-
tion by suppressing the excess cytokine production from acti-
vated T lymphocytes and monocytes, and cellular activation in
glomeruli.
In summary, the aberrant expression of HLA-DQ antigen in
glomeruli and serum y-IFN levels are related to the activity of
human LN, and these abnormal cytokine production and intra-
glomerular cellular activation could be improved by methyl-
prednisolone pulse therapy. These results suggest that MHC-
class II molecules and y-IFN may play an important role in
immune-mediated glomerular injury of human LN.
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